Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 -2.18%8 Return-on-Tangible-Equity is 79.48% as of Dec. 2025, which is 1674% above its 10-year median of 4.48. GuruFocus rates ROCO:7731 with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 576 Healthcare Providers & Services companies, MARX Biotech Co ranks better than 70.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MARX Biotech Co's annualized net income for the quarter that ended in Dec. 2025 was NT$161.9 Mil. MARX Biotech Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$203.7 Mil. Therefore, MARX Biotech Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 79.48%.
The historical rank and industry rank for MARX Biotech Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:7731'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -46.42 Med: 4.48 Max: 22.71
Current: 22.71
During the past 6 years, MARX Biotech Co's highest Return-on-Tangible-Equity was 22.71%. The lowest was -46.42%. And the median was 4.48%.
ROCO:7731's Return-on-Tangible-Equity is ranked better than 70.66% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs ROCO:7731: 22.71
MARX Biotech Co (ROCO:7731) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MARX Biotech Co Return-on-Tangible-Equity Related Terms
MARX Biotech Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MARX Biotech Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 79.48% mean?
MARX Biotech Co (ROCO:7731) has a Return-on-Tangible-Equity of 79.48% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MARX Biotech Co and its competitors. This is 1674% above median its historical median of 4.48. According to the industry distribution chart, MARX Biotech Co ranks #169 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 29.3%.
Is MARX Biotech Co's Return-on-Tangible-Equity too high?
MARX Biotech Co's current Return-on-Tangible-Equity of 79.48% is 1674% above median its 10-year median of 4.48. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. MARX Biotech Co's value of 79.48% is 681.5% above this industry median. Based on the distribution chart, MARX Biotech Co ranks #169 out of 576 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MARX Biotech Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #169 out of 576 companies for Return-on-Tangible-Equity. This puts MARX Biotech Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.17. MARX Biotech Co's value of 79.48% is 681.5% above this benchmark. While the company's 10-year median is 4.48 vs. the industry median of 10.17, MARX Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MARX Biotech Co's current Return-on-Tangible-Equity of 79.48% is 681.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current Return-on-Tangible-Equity is 79.48%, which is 1674% above median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current Return-on-Tangible-Equity of 79.48%. The current Return-on-Tangible-Equity is 79.48%, which is 1674% above median its 10-year median of 4.48 and 681.5% above the Healthcare Providers & Services industry median of 10.17. MARX Biotech Co's overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current Return-on-Tangible-Equity is 79.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
8GF Score
Get the complete analysis for ROCO:7731
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
